5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients
- PMID: 18443386
5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients
Abstract
DPYD gene encodes dihydropyrimidine dehydrogenase which is the initial and rate-limiting enzyme in the metabolism of 5-fluorouracil (5-FU). The aim of our study was PCR-RFLP based-genetic testing for the most common 5-FU toxicity-attributable IVS14 + 1G > A DPYD mutation (DPYD(*)2A) in 252 Polish colorectal cancer (CRC) patients treated with this adjuvant chemotherapeutic regimen after surgery. The DPYD(*)2A allele was identified only in one patient: a male who was one of 4 CRC patients suffering from grades 3-4 myelotoxicity upon 5-FU chemotherapy. We conclude that IVS14 + 1G > A DPYD (DPYD(*)2A) variant occurs in the Polish population and is responsible for a significant proportion of life-threatening toxicity of 5-FU.
Similar articles
-
Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.Br J Clin Pharmacol. 2010 Aug;70(2):268-72. doi: 10.1111/j.1365-2125.2010.03683.x. Br J Clin Pharmacol. 2010. PMID: 20653680 Free PMC article.
-
Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.Anticancer Res. 2007 Nov-Dec;27(6B):3899-902. Anticancer Res. 2007. PMID: 18225548
-
[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29. Magy Onkol. 2007. PMID: 17660867 Hungarian.
-
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.Eur J Cancer. 2004 May;40(7):939-50. doi: 10.1016/j.ejca.2003.12.004. Eur J Cancer. 2004. PMID: 15093568 Review.
-
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.Pharmacogenomics. 2013 Aug;14(11):1255-72. doi: 10.2217/pgs.13.116. Pharmacogenomics. 2013. PMID: 23930673
Cited by
-
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.PLoS One. 2013 Oct 22;8(10):e78053. doi: 10.1371/journal.pone.0078053. eCollection 2013. PLoS One. 2013. PMID: 24167597 Free PMC article. Clinical Trial.
-
DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Ont Health Technol Assess Ser. 2021 Aug 12;21(14):1-186. eCollection 2021. Ont Health Technol Assess Ser. 2021. PMID: 34484488 Free PMC article. Review.
-
Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.J Clin Lab Anal. 2021 Nov;35(11):e24023. doi: 10.1002/jcla.24023. Epub 2021 Oct 6. J Clin Lab Anal. 2021. PMID: 34612540 Free PMC article.
-
DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.J Pers Med. 2018 Dec 13;8(4):45. doi: 10.3390/jpm8040045. J Pers Med. 2018. PMID: 30551678 Free PMC article.
-
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.Hum Genet. 2022 Jun;141(6):1113-1136. doi: 10.1007/s00439-021-02385-x. Epub 2021 Oct 15. Hum Genet. 2022. PMID: 34652573 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases